Bbs Bioactive Bone Substitutes Stock Last Dividend Paid
| BONEH Stock | EUR 0.07 0 1.47% |
BBS Bioactive Bone Substitutes fundamentals help investors to digest information that contributes to BBS Bioactive's financial success or failures. It also enables traders to predict the movement of BBS Stock. The fundamental analysis module provides a way to measure BBS Bioactive's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BBS Bioactive stock.
BBS |
BBS Bioactive Bone Substitutes Company Last Dividend Paid Analysis
BBS Bioactive's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, BBS Bioactive Bone Substitutes has a Last Dividend Paid of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Medical Devices (which currently averages 0.0) industry. This indicator is about the same for all Finland stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
BBS Fundamentals
| Return On Equity | -0.61 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (278.58) % | |||
| Current Valuation | 14.53 M | |||
| Shares Outstanding | 9.67 M | |||
| Shares Owned By Insiders | 45.74 % | |||
| Shares Owned By Institutions | 1.71 % | |||
| Price To Book | 2.10 X | |||
| Price To Sales | 1,123 X | |||
| Gross Profit | (56.95 K) | |||
| EBITDA | (2.34 M) | |||
| Net Income | (2.77 M) | |||
| Cash And Equivalents | 3.44 M | |||
| Cash Per Share | 0.52 X | |||
| Total Debt | 5.12 M | |||
| Debt To Equity | 0.99 % | |||
| Current Ratio | 5.04 X | |||
| Book Value Per Share | 0.58 X | |||
| Cash Flow From Operations | (2.52 M) | |||
| Earnings Per Share | (0.42) X | |||
| Number Of Employees | 21 | |||
| Beta | -0.0943 | |||
| Market Capitalization | 12.23 M | |||
| Total Asset | 10.51 M | |||
| Z Score | 1.2 | |||
| Net Asset | 10.51 M |
About BBS Bioactive Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BBS Bioactive Bone Substitutes's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BBS Bioactive using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BBS Bioactive Bone Substitutes based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BBS Stock
BBS Bioactive financial ratios help investors to determine whether BBS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BBS with respect to the benefits of owning BBS Bioactive security.